GALD.SW stock trades at CHF144.90 intraday on the SIX exchange in Switzerland as markets anticipate Galderma Group N’s earnings on 05 Mar 2026. Volume is light at 76,725 shares versus an average of 379,102, and the stock is down -0.69% today. Investors will focus on margin detail and guidance from Injectable Aesthetics and Dermatological Skincare segments. We summarise the numbers, valuation gaps, and the key catalysts ahead of the report.

GALD.SW stock: Intraday price, range and flow

The most current intraday price is CHF144.90, with a day low of CHF143.10 and a day high of CHF145.60. The stock opened at CHF144.00 and the previous close was CHF145.90. Volume at 76,725 shares equals a relative volume of 0.65, showing below-average trading ahead of earnings.

GALD.SW stock: Earnings setup and near-term catalysts

Galderma will report results on 05 Mar 2026, making guidance and margin commentary the primary catalysts. Management commentary on Injectable Aesthetics growth and therapeutic dermatology mix often moves the stock more than top-line beats. Analysts will also watch any changes to FY guidance and regional demand trends for Europe and North America.

GALD.SW stock: Fundamentals, valuation and sector context

Galderma shows EPS 1.23 and the quoted market PE near 120.00, well above the Consumer Defensive sector average PE of 28.32. Market capitalisation is CHF34.66B with 234,823,853 shares outstanding. Price relative to moving averages is mixed: 50-day 154.55 and 200-day 139.59, indicating near-term resistance and longer-term support.

GALD.SW stock: Key financial ratios and cash flow metrics

Trailing metrics show a price-to-sales ratio of 7.61, EV/EBITDA around 36.12, and free cash flow per share of 3.08. Debt is modest versus equity with debt-to-equity at 0.37 and net debt to EBITDA approximately 2.33. Operating margin sits near 15.15%, so margin expansion is the straightest route to justify current valuation.

GALD.SW stock: Technical picture and trading cues

Technicals are neutral-to-cautious: RSI 44.38, MACD histogram slightly negative, and ATR 4.27. Bollinger Bands midpoint is 149.34, so a close above that would suggest upside momentum. Watch intraday volume spikes on any guidance changes and the 50-day average at 154.55 as a resistance zone.

GALD.SW stock: Meyka grade and model forecast

Meyka AI rates GALD.SW with a score out of 100: 70.68, Grade B+, Suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of CHF207.05, implying an upside of 42.91% versus the current CHF144.90, while noting model-based projections are not guarantees. For more company detail see Galderma investor pages Galderma – Investors and the company site Galderma. Internal research tools are available on our platform Meyka stock page.

Final Thoughts

GALD.SW stock trades at CHF144.90 intraday on 03 Mar 2026 with light volume ahead of the 05 Mar 2026 earnings release. The immediate market question is whether Galderma can show margin improvement in Injectable Aesthetics and Dermatological Skincare. Valuation is elevated, with a quoted PE near 120.00 and EV/EBITDA around 36.12, so the stock needs clear operating leverage to justify current levels. Meyka AI’s forecast model projects a yearly target of CHF207.05, implying +42.91% upside versus today’s price, while also flagging valuation risk if margins disappoint. Traders should watch intraday volume, management commentary on guidance, and the 50-day average at CHF154.55 for tactical signals. These figures and scenarios reflect model outputs and Meyka AI’s grade; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.